Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil

Internal Medicine

Volumn 46, Issue 9, 2007, Pages 565-569

  Miyake, Yasuhiro ^a   Iwasaki, Yoshiaki ^a   Shiraha, Hidenori ^a   Sakaguchi, Kohsaku ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Extrahepatic metastasis; Systemic chemotherapy

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2B INTERFERON; ANTIBIOTIC AGENT; CISPLATIN; DECARBOXYPROTHROMBIN; FLUOROURACIL; HEPATITIS ANTIBODY; UFT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; TEGAFUR;

AGED; ANOREXIA; ARTICLE; ASCITES; CASE REPORT; CELLULITIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LEG SWELLING; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; NAUSEA; PERIPHERAL EDEMA; PERITONEUM METASTASIS; PROTEIN BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PERITONEUM TUMOR; RADIOGRAPHY; RETREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FATIGUE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; LIVER NEOPLASMS; MALE; NAUSEA; PERITONEAL NEOPLASMS; RETREATMENT; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34249658320     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6362     Document Type: Article

References (21)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16, 2004.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
3. Ikai I, Arii S, Ichida T, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 32: 163-172, 2005.
4. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101: 796-802, 2004.
5. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 62: S69-S73, 2002.
6. Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93: 557-564, 2005.
7. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88: 1986-1991, 2000.
8. Miyamoto A, Umeshita K, Sakon M, et al. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 15: 1447-1451, 2000.
9. Ikeda K, Saitoh S, Koida I, et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18: 204-210, 1995.
10. Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 16: 452-459, 2001.
11. Maeda T, Itasaka H, Takenaka K, et al. Low-dose cisplatin plus oral tegafur and uracil for the treatment of lung metastases of hepatocellular carcinoma. Hepatogastroenterology 50: 1583-1586, 2003.
12. Seki S, Yamada T, Kawakita N, Masuichi H, Kitada T, Sakaguchi H. A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma. Hepatogastroenterology 50: 1598-1602, 2003.
13. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3: 395-399, 1997.
14. Sonoda, T, Kanematsu T, Takenaka. K, Sugimachi K. Ruptured hepatocellular carcinoma evokes risk of implanted metastases. J Surg Oncol 41: 183-186, 1989.
15. Eriguchi N, Aoyagi S, Okuda K, et al. Successful surgical treatment for implanted intraperitoneal metastases of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 7: 520-523, 2000.
16. Nakayama H, Takayama T, Makuuchi M, et al. Resection of peritoneal metastases from hepatocellular carcinoma. Hepatogastroenterology 46: 1049-1052, 1999.
17. Yoshida H, Onda M, Tajiri T, et al. Successful surgical treatment of peritoneal dissemination of hepatocellular carcinoma. Hepatogastroenterology 49: 1663-1665, 2002.
18. Sato M, Tokui K, Watanabe Y, et al. Generalized intraperitoneal seeding of hepatocellular carcinoma after microwave coagulation therapy: a case report. Hepatogastroenterology 46: 2561-2564, 1999.
19. Miki K, Makuuchi M, Takayama T, et al. Peritoneal seeding of hepatocellular carcinoma after ethanol injection therapy. Hepatogastroenterology 47: 1428-1430, 2000.
20. Takahashi H, Konishi M, Nakagohri T, et al. Aggressive multimodal treatment for peritoneal dissemination and needle tract implantation of hepatocellular carcinoma: a case report. Jpn J Clin Oncol 34: 551-555, 2004.
21. Uenishi T, Kubo S, Hirohashi K, et al. Successful surgical control for hepatocellular carcinoma disseminated to the peritoneum: a case report. Hepatogastroenterology 49: 532-534, 2002.